NefPONCT04576078
Post-operative Analgesic Effect of Oral Nefopam
StatusActive, Not Recruiting
PhasePhase 2
SponsorHospices Civils de Lyon
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 10 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 4 of 13 entries
- Site details revised
- Notable Primary completion date: Jun 30, 2026 to Dec 30, 2026
- Enrollment target: 40 to 50
- Study completion date: Nov 15, 2026 to May 15, 2027
- Site details revised
- Notable Primary completion date: Jun 30, 2024 to Jun 30, 2026
- Study completion date: Nov 15, 2024 to Nov 15, 2026
Notable Enrollment target: 58 to 40v3 Show 4 more changesShow less
- Primary completion date: Jul 30, 2023 to Jun 30, 2024
- Eligibility criteria revised
- Study completion date: Nov 15, 2023 to Nov 15, 2024
- Secondary endpoints: 12 to 13
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
- Primary completion date: Oct 2022 to Jul 30, 2023
- Start date changed from estimate of Oct 2020 to Jun 29, 2021
- Study sites: 0 to 1
- Study completion date: Feb 2023 to Nov 15, 2023
- Study title shortened, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Total morphine consumption within 24h after the surgery.
Timeframe: 24 hours after the surgery.
Secondary (13)
Hyperalgesia - Pressure Pain Threshold
Hyperalgesia - Punctate Pain Intensity
Hyperalgesia - Allodynia zone
Pain intensity
Self reported safety outcomes
Show 8 moreShow less
Measures Safety outcomes
Pharmacokinetics:Plasmatic and cerebrospinal fluid concentration of nefopam
Pharmacokinetics:Plasmatic and cerebrospinal fluid concentration of nefopam-beta-D-glucuronide
Pharmacokinetics:Plasmatic and cerebrospinal fluid concentration of nefopam-N-oxyde
Pharmacokinetics:Plasmatic and cerebrospinal fluid concentration of nefopam-N-demethyl
Pharmacokinetics:Plasmatic and cerebrospinal fluid concentration of Nefopam hydrochloride
Persistent postoperative pain - DN4 (or DN2 by phone)
Persistent postoperative pain - DN4
Arms and interventions
NEFOPAM 60mg PO/ 8 hoursExperimental
Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h.
PlaceboPlacebo comparator
Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h.
Drugs: Oral nefopam, Placebo
Sites
1 site in 1 country
- Département d'Anesthésie Réanimation, Groupement Hospitalier Nord, Hospices Civils de LyonLyon, France